PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26030092-2	2015	In a previous study we showed that stathmin increases vinblastine (VLB) binding to tubulin, and that conversely VLB increases stathmin binding to tubulin.	Vinblastine	54-65	stathmin 1	Homo sapiens	35-43	
28259950-0	2017	Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.	Vinblastine	0-11	stathmin 1	Homo sapiens	123-127	
28259950-0	2017	Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.	Vinblastine	0-11	stathmin 1	Homo sapiens	128-136	
25944168-2	2015	Several studies have shown that overexpression of STMN1 has been linked to chemoresistance of paclitaxel and vinblastine in tumor cells.	Vinblastine	109-120	stathmin 1	Homo sapiens	50-55	
25944168-3	2015	This study aimed to investigate the effects of STMN1 silencing on chemosensitivities of paclitaxel or vinblastine in esophageal squamous cell carcinoma (ESCC).	Vinblastine	102-113	stathmin 1	Homo sapiens	47-52	
26030092-8	2015	Taken together with the previous study using vinblastine, our results suggest that stathmin can be seen as a modulator of MTA activity and binding to tubulin, providing molecular explanation for multiple previous cellular and in vivo studies showing that stathmin expression level affects MTAs efficiency.	Vinblastine	45-56	stathmin 1	Homo sapiens	83-91	
26030092-8	2015	Taken together with the previous study using vinblastine, our results suggest that stathmin can be seen as a modulator of MTA activity and binding to tubulin, providing molecular explanation for multiple previous cellular and in vivo studies showing that stathmin expression level affects MTAs efficiency.	Vinblastine	45-56	stathmin 1	Homo sapiens	255-263	
18588888-0	2008	Stathmin/Op18 is a novel mediator of vinblastine activity.	Vinblastine	37-48	stathmin 1	Homo sapiens	0-8	
22407961-4	2012	Nocodazole or vinblastine-induced MT depolymerization abrogated the stathmin-depletion induced G2 delay, measured by the percentage of cells staining positive for several markers (TPX2, CDK1 with inhibitory phosphorylation), indicating that MTs are required to lengthen G2.	Vinblastine	14-25	stathmin 1	Homo sapiens	68-76	
18588888-0	2008	Stathmin/Op18 is a novel mediator of vinblastine activity.	Vinblastine	37-48	stathmin 1	Homo sapiens	9-13	
18588888-2	2008	Studies in cells have indicated that the level of stathmin expression modifies the cytotoxicity of antimicrotubule drugs, such as vinblastine (VLB).	Vinblastine	130-141	stathmin 1	Homo sapiens	50-58	
18588888-2	2008	Studies in cells have indicated that the level of stathmin expression modifies the cytotoxicity of antimicrotubule drugs, such as vinblastine (VLB).	Vinblastine	143-146	stathmin 1	Homo sapiens	50-58	
17663418-5	2007	Loss of stathmin expression increased responsiveness of tumor cells to the treatment with cytostatic drugs targeting MT-stability (paclitaxel, vinblastine) and to DNA cross-linking agents (cisplatin).	Vinblastine	143-154	stathmin 1	Homo sapiens	8-16	
17272681-0	2007	Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.	Vinblastine	59-70	stathmin 1	Homo sapiens	12-20	
17272681-6	2007	We found that targeting stathmin or wee-1 expression with RNA interference can induce microtubule polymerization and promote G(2)/M progression, respectively, and sensitize stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine.	Vinblastine	235-246	stathmin 1	Homo sapiens	24-32	
16940412-6	2006	Of the two tubulin structures available, we selected for modeling the complex of a stathmin fragment with two tubulin heterodimers with two bound colchicinoid molecules and a single bound vinblastine between the two heterodimers (Nature (Lond) 435:519-522, 2005).	Vinblastine	188-199	stathmin 1	Homo sapiens	83-91	
12460900-6	2002	Overexpression of stathmin decreased polymerization of microtubules, markedly decreased binding of paclitaxel, and increased binding of vinblastine.	Vinblastine	136-147	stathmin 1	Homo sapiens	18-26	
12460900-7	2002	Stathmin overexpression decreased sensitivity to paclitaxel and, to a lesser extent, to vinblastine.	Vinblastine	88-99	stathmin 1	Homo sapiens	0-8	
12460900-10	2002	This effect was magnified when stathmin-overexpressing cells were treated with vinblastine as measured by the detection of proteins phosphorylated in early mitosis.	Vinblastine	79-90	stathmin 1	Homo sapiens	31-39	
11181174-7	2001	In contrast, stathmin inhibition results in decreased sensitivity to vinblastine, an agent that destabilizes the mitotic spindle.	Vinblastine	69-80	stathmin 1	Homo sapiens	13-21